PROT, Proteonomix, Inc., PROT.OB

PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of PROT that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products.

PROT has developed a catalog of intellectual properties and patent applications. These technologies are designed to work together in a synergistic fashion.

** PROT recently reported that it has formed a new subsidiary called X Gen Medical LLC, a Nevis Virgin Island entity.

PROT's X Gen Medical has been established with the intention of conducting business in the global medical marketplace.

PROT plans on utilizing X Gen Medical to serve as a platform for joint ventures with medical facilities worldwide.

It is anticipated that new relationships formed with X Gen Medical will create medical facilities capable of not just attracting treatments locally, but also acting as hubs for medical tourism.

Individuals have practiced medical tourism for thousands of years. In ancient Greece , pilgrims traveled all over the Mediterranean to the healing god, Asklepios, at Epidaurus. In Roman Britain, patients traversed the countryside in hopes of curing ailments at the shrine at Bath. Europeans traveled to Germany and the Nile for curative waters and Ireland for soaking in tubs of Irish sea moss.

Medical tourism is constantly on the rise and anticipated to continue to grow substantially due to current high costs of health care for certain procedures and improvements in both technology and standards of care in many countries.

Mr. Michael Cohen, Chairman and CEO of PROT, stated, “We have been in negotiations with several groups, specifically in the Middle East and Europe, to establish Proteonomix Regenerative Translational Medicine Institute (”PRTMI”) medical facilities in those regions. The negotiations have reached the level whereby the establishment of a separate subsidiary, X Gen Medical LLC., was essential in order to allow Proteonomix to properly enter these global markets with the intention of soliciting business through our proprietary PRTMI model. We anticipate closing on some of these negotiations in the near future, which we anticipate will include the necessary funding required to firmly establish X Gen Medical as a PRTMI provider.”

Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine.

More about PROT at www.proteonomix.com

****

MDT, Medtronic, Inc

MDT is the world's leading medical technology company, alleviating pain, restoring health, and extending life for people with chronic disease.

** MDT reported that it will report financial results for the first quarter of its fiscal year 2011 on Tuesday, August 24, 2010.

A news release will be issued at approximately 6:15 a.m. Central Time and will be available at www.medtronic.com/newsroom. The earnings news release will include summary financial information for MDT's first quarter ended July 30, 2010.

MDT will host a webcast at 7 a.m. Central Time to discuss financial results for its first quarter. The webcast can be accessed by clicking on the Investors link through the Medtronic website.

Within 24 hours of the webcast, a replay, podcast, and transcript of the prepared remarks will be available under the Events and Presentations page in the Investors section of MDT's website.

More about MDT at www.medtronic.com

****

HGSI, Human Genome Sciences Inc.

HGSI operates as a biopharmaceutical company in the United States.

HGSI's clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of BENLYSTA for systemic lupus erythematosus; ZALBIN for chronic hepatitis C; and raxibacumab for inhalation anthrax.

HGSI reported that Tuomo Pätsi has joined the Company as Vice President, HGS Europe. Mr. Pätsi, formerly Regional Vice President – Northern Europe at Celgene International, will be responsible for European sales, marketing and medical affairs across the HGS product portfolio, and will report to Barry A. Labinger, Executive Vice President and Chief Commercial Officer.

More about HGSI at www.hgsi.com

****

Newsletter at http://www.pennyotcstock.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOtcStock.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyotcstock.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB).